Conexeu Sciences Lists on Nasdaq with Scalable CXU™ Tissue Platform
CNXU•Conexeu Sciences began Nasdaq trading May 21, 2026 as a preclinical-stage regenerative tissue platform targeting wound care, breast reconstruction and aesthetic medicine with its scalable CXU™ technology. It holds patents across U.S., EU, Japan and Australia with no royalties, plans a 510(k) submission for its B.R.E.A.S.T.™ scaffold in early 2027.
1. Nasdaq Debut
Conexeu Sciences Inc began trading on Nasdaq on May 21, 2026 under the symbol CNXU as a preclinical-stage regenerative medicine company. The listing provides capital access to advance its extracellular matrix platform across wound care, breast reconstruction and aesthetic medicine.
2. CXU™ Platform and Product Pipeline
The proprietary CXU™ extracellular matrix technology is designed to transition from fluid at room temperature to a stable gel in situ within ten minutes, supporting tissue regeneration without reformulation. Early expressions include the injectable Ten Minute Tissue™ and the B.R.E.A.S.T.™ 3D-bioprinted scaffold for mastectomy reconstruction.
3. Intellectual Property and Regulatory Pathway
Conexeu holds issued patents across U.S., EU, Japan and Australia with no royalty obligations, ensuring freedom to operate. The company plans to submit a 510(k) application for the B.R.E.A.S.T.™ scaffold in early 2027 to initiate regulatory review for its initial indication.
